{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T12:41:33Z","timestamp":1784724093427,"version":"3.55.0"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,6,2]],"date-time":"2022-06-02T00:00:00Z","timestamp":1654128000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>Congenital hyperinsulinism (HI) is the most frequent cause of severe, persistent hypoglycemia in newborn babies and children. There are many areas of need for HI research. Some of the most critical needs include describing the natural history of the disease, research leading to new and better treatments, and identifying and managing hypoglycemia before it is prolonged and causes brain damage or death. Patient-reported data provides a basis for understanding the day-to-day experience of living with HI. Commonly identified goals of registries include performing natural history studies, establishing a network for future product and treatment studies, and supporting patients and families to offer more successful and coordinated care. Congenital Hyperinsulinism International (CHI) created the HI Global Registry (HIGR) in October 2018 as the first global patient-powered hyperinsulinism registry. The registry consists of thirteen surveys made up of questions about the patient\u2019s experience with HI over their lifetime. An international team of HI experts, including family members of children with HI, advocates, clinicians, and researchers, developed the survey questions. HIGR is managed by CHI and advised by internationally recognized HI patient advocates and experts. This paper aims to characterize HI through the experience of individuals who live with it. This paper includes descriptive statistics on the birthing experience, hospitalizations, medication management, feeding challenges, experiences with glucose monitoring devices, and the overall disease burden to provide insights into the current data in HIGR and demonstrate the potential areas of future research. As of January 2022, 344 respondents from 37 countries consented to participate in HIGR. Parents or guardians of individuals living with HI represented 83.9% of the respondents, 15.3% were individuals living with HI. Data from HIGR has already provided insight into access challenges, patients\u2019 and caregivers\u2019 quality of life, and to inform clinical trial research programs. Data is also available to researchers seeking to study the pathophysiology of HI retrospectively or to design prospective trials related to improving HI patient outcomes. Understanding the natural history of the disease can also guide standards of care. The data generated through HIGR provides an opportunity to improve the lives of all those affected by HI.<\/jats:p>","DOI":"10.3389\/fendo.2022.876903","type":"journal-article","created":{"date-parts":[[2022,6,2]],"date-time":"2022-06-02T11:52:09Z","timestamp":1654170729000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":25,"title":["Global Registries in Congenital Hyperinsulinism"],"prefix":"10.3389","volume":"13","author":[{"given":"Tai L. S.","family":"Pasquini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahlet","family":"Mesfin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Schmitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Raskin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,6,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-3651","article-title":"Perspective on the Genetics and Diagnosis of Congenital Hyperinsulinism Disorders","volume":"101","author":"Stanley","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.c.31737","article-title":"Congenital Hyperinsulinism Disorders: Genetic and Clinical Characteristics","volume":"181","author":"Rosenfeld","year":"2019","journal-title":"Am J Med Genet C Semin Med Genet"},{"key":"B3","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1111\/dme.13823","article-title":"Therapies and Outcomes of Congenital Hyperinsulinism-Induced Hypoglycaemia","volume":"36","author":"Banerjee","year":"2019","journal-title":"Diabetes Med J Br Diabetes Assoc"},{"key":"B4","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/1750-1172-6-63","article-title":"Congenital Hyperinsulinism: Current Trends in Diagnosis and Therapy","volume":"6","author":"Arnoux","year":"2011","journal-title":"Orphanet J Rare Dis"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s40290-020-00332-1","article-title":"Establishing Patient Registries for Rare Diseases: Rationale and Challenges","volume":"34","author":"Boulanger","year":"2020","journal-title":"Pharm Med"},{"key":"B6","doi-asserted-by":"crossref","DOI":"10.23970\/AHRQEPCREGISTRIES4","volume-title":"Registries for Evaluating Patient Outcomes: A User\u2019s Guide","author":"Gliklich","year":"2020"},{"key":"B7","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/978-90-481-9485-8_6","article-title":"Patient Registries: Utility, Validity and Inference","volume":"686","author":"Richesson","year":"2010","journal-title":"Adv Exp Med Biol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s13023-018-0836-0","article-title":"Rare Disease Registries: Potential Applications Towards Impact on Development of New Drug Treatments","volume":"13","author":"Jansen-van der Weide","year":"2018","journal-title":"Orphanet J Rare Dis"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-014-2892-z","article-title":"Patient-Reported Outcomes in Clinical Trials of Rare Diseases","author":"Basch","year":"2014","journal-title":"J Gen Intern Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1186\/s13023-019-1139-9","article-title":"RD-RAP: Beyond Rare Disease Patient Registries, Devising a Comprehensive Data and Analytic Framework","volume":"14","author":"Bellgard","year":"2019","journal-title":"Orphanet J Rare Dis"},{"key":"B11","volume-title":"Real-World Data: Assessing Registries to Support Regulatory Decision-Making for Drug and Biological Products Guidance for Industry. FDA-2021-D-1146. [Internet]","year":"2021"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/pds.4962","article-title":"Use of Real-World Evidence in Regulatory Decisions for Rare Diseases in the United States-Current Status and Future Directions","volume":"29","author":"Wu","year":"2020","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"B13","doi-asserted-by":"publisher","first-page":"11968","DOI":"10.3390\/ijerph182211968","article-title":"The Quality Evaluation of Rare Disease Registries\u2014An Assessment of the Essential Features of a Disease Registry","volume":"18","author":"Ali","year":"2021","journal-title":"Int J Environ Res Public Health"},{"key":"B14","doi-asserted-by":"publisher","first-page":"E1644","DOI":"10.3390\/ijerph15081644","article-title":"Recommendations for Improving the Quality of Rare Disease Registries","volume":"15","author":"Kodra","year":"2018","journal-title":"Int J Environ Res Public Health"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-67144-4_8","article-title":"Data Quality in Rare Diseases Registries","volume":"1031","author":"Kodra","year":"2017","journal-title":"Adv Exp Med Biol"},{"key":"B16","unstructured":"Critical Path Institute"},{"key":"B17","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1111\/cch.12628","article-title":"\u201cIt is Like a Jungle Gym, and Everything is Under Construction\u201d: The Parent\u2019s Perspective of Caring for a Child With a Rare Disease","volume":"45","author":"Currie","year":"2019","journal-title":"Child Care Health Dev"},{"key":"B18","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1007\/s10897-018-0294-9","article-title":"Alone in a Crowd? Parents of Children With Rare Diseases\u2019 Experiences of Navigating the Healthcare System","volume":"28","author":"Baumbusch","year":"2018","journal-title":"J Genet Couns"},{"key":"B19","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1186\/s13023-021-01943-w","article-title":"Navigating the U.S. Health Insurance Landscape for Children With Rare Diseases: A Qualitative Study of Parents\u2019 Experiences","volume":"16","author":"Pasquini","year":"2021","journal-title":"Orphanet J Rare Dis"},{"key":"B20","doi-asserted-by":"publisher","first-page":"dgaa543","DOI":"10.1210\/clinem\/dgaa543","article-title":"Management and Appropriate Use of Diazoxide in Infants and Children With Hyperinsulinism","volume":"105","author":"Brar","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"B21","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1159\/000497458","article-title":"Rate of Serious Adverse Events Associated With Diazoxide Treatment of Patients With Hyperinsulinism","volume":"91","author":"Thornton","year":"2019","journal-title":"Horm Res Paediatr"},{"key":"B22","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1186\/s13023-018-0970-8","article-title":"Characterization of Diabetes Following Pancreatic Surgery in Patients With Congenital Hyperinsulinism","volume":"13","author":"Welters","year":"2018","journal-title":"Orphanet J Rare Dis"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-2539","article-title":"High Risk of Diabetes and Neurobehavioral Deficits in Individuals With Surgically Treated Hyperinsulinism","volume":"100","author":"Lord","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1002\/ijgo.13195","article-title":"Global Burden of Preterm Birth","volume":"150","author":"Walani","year":"2020","journal-title":"Int J Gynecol Obstet"},{"key":"B25","unstructured":"Weight-For-Age"},{"key":"B26","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.jpedsurg.2018.10.030","article-title":"Surgical Treatment of Congenital Hyperinsulinism: Results From 500 Pancreatectomies in Neonates and Children","volume":"54","author":"Adzick","year":"2019","journal-title":"J Pediatr Surg"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0098054","article-title":"Pancreatic Endocrine and Exocrine Function in Children Following Near-Total Pancreatectomy for Diffuse Congenital Hyperinsulinism","volume":"9","author":"Arya","year":"2014","journal-title":"PloS One"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.876903\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,2]],"date-time":"2022-06-02T11:52:15Z","timestamp":1654170735000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.876903\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,2]]},"references-count":27,"alternative-id":["10.3389\/fendo.2022.876903"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2022.876903","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,2]]},"article-number":"876903"}}